Key references: Systemic MHT in specific patient groups
Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;(3):CD002229. https://www.ncbi.nlm.nih.gov/pubmed/25754617
Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update 2017;23(4):481–500. https://www.ncbi.nlm.nih.gov/pubmed/28498913
Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric 2018;21(3):256–66. https://www.ncbi.nlm.nih.gov/pubmed/29521155
Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric 2012;15(3):256–62. https://www.ncbi.nlm.nih.gov/pubmed/22612612
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310(13):1353–68. https://www.ncbi.nlm.nih.gov/pubmed/24084921
Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update 2019;25(2):257–71. https://www.ncbi.nlm.nih.gov/pubmed/30508190
Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519. https://www.ncbi.nlm.nih.gov/pubmed/20525678
Ropponen A, Aittomaki K, Vihma V, Tikkanen MJ, Ylikorkala O. Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 2005;90(6):3431–4. https://www.ncbi.nlm.nih.gov/pubmed/15784702
Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb Res 2018;168:83–95. https://www.ncbi.nlm.nih.gov/pubmed/29936403
Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), Women’s Health Committee. Menopausal hormone therapy advice [Under review]. Melbourne: RANZCOG; 2012 (reviewed 2015). https://ranzcog.edu.au/statements-guidelines/
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1–s66. https://www.ncbi.nlm.nih.gov/pubmed/20566620
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810. https://www.ncbi.nlm.nih.gov/pubmed/30626577
